EP Patent

EP4601615A1 — Liquid dalbavancin composition

Assigned to Hikma Pharmaceuticals USA Inc · Expires 2025-08-20 · 1y expired

What this patent protects

The present disclosure relates to a stable aqueous composition of dalbavancin, the process for making such compositions and use of such compositions for treatment of a patient in need thereof.

USPTO Abstract

The present disclosure relates to a stable aqueous composition of dalbavancin, the process for making such compositions and use of such compositions for treatment of a patient in need thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP4601615A1
Jurisdiction
EP
Classification
—
Expires
2025-08-20
Drug substance claim
No
Drug product claim
No
Assignee
Hikma Pharmaceuticals USA Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.